17 Sep 2021

Ginkgo BioWorks

Ginkgo Bioworks develops biotechnology products. It engages in strain engineering, mammal cell engineering, ferment discovery and DNA synthesis. The company plans to use these technologies to produce next-generation antibiotics and nucleic acid vaccines, program microbes to cure stomach diseases, grow food using the fermentation process, make microbiome agriculture products and more. In addition, Ginkgo conducts COVID-19 testing, with over 90 million people already tested. The company also has its own software, codebase and automations for R&D. Ginkgo Bioworks is headquartered in Boston, Massachusetts.

NewsHeat chart

Week
Month
Year

Media news
Corp news

Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

Valuation
Share Price
Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round

Funding Amount

Post-Money Valuation

Share Price

Series F15 May, 2020

***

Series E19 Sep, 2019

***

Series D13 Dec, 2017

***

Series C8 Jun, 2016

***

Series B8 Jul, 2015

***

Series A18 Mar, 2015

***

*** - To view the data, please log into your account or create a new one.

News related to Ginkgo BioWorks114

Sort by

Ginkgo BioWorks

Jan 10, 2025 •Show on chart

Botswana’s Ministry of Health and Ginkgo Launch Pathogen Monitoring Program at Sir Seretse Khama International Airport | Ginkgo Bioworks

Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals....

Ginkgo BioWorks https://www.ginkgo.bio/resources/blog/botswanas-ministry-of-health-and-ginkgo-launch-pathogen-monitoring-program

Ginkgo BioWorks

Jan 10, 2025 •Show on chart

Ginkgo Biosecurity and Virgin Atlantic Partner for Cutting-Edge Biosecurity | Ginkgo Bioworks

Ginkgo BioWorks https://www.ginkgo.bio/resources/blog/ginkgo-biosecurity-and-virgin-atlantic-partner-for-cutting-edge-biosecurity

Ginkgo BioWorks

May 3, 2024 •Show on chart

Ginkgo Bioworks Announces Date of First Quarter 2024 Results Presentation - Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and QA session reviewing business performance for the first quarter end...

Ginkgo BioWorks https://www.ginkgobioworks.com/press/ginkgo-bioworks-announces-date-of-first-quarter-2024-results-presentation/

Ginkgo BioWorks

May 3, 2024 •Show on chart

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors - Ginkgo Bioworks

Today, Ginkgo Bioworks (NYSE: DNA ), which is building the leading platform for cell programming and biosecurity, announced the nomination of Myrtle Potter and Ross Fubini for election as independent directors at Ginkgo's upcoming annual meeting, schedule...

Ginkgo BioWorks https://www.ginkgobioworks.com/press/ginkgo-bioworks-announces-nomination-of-myrtle-potter-and-ross-fubini-to-board-of-directors/

Ginkgo BioWorks

Sep 15, 2021 •Show on chart